Although the number of clinical trials assessing the use of immunotherapy in BC is increasing, to date, the approval of its use is only for a selected subset of advanced triple-negative (TN) BC patients with >1% of programmed death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) [6,14]. The gene discussed is CD274; the disease is breast cancer.